Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib identifier:
NCT04550494 (

Treatment study for people with advanced solid tumors

Study Contact Information:

Lead Researcher: A.P. Chen, MD
Contact: [email protected] 
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, MD

About the Study

This study is looking whether the drug talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes. Talazoparib is a type of targeted therapy known as a PARP inhibitor. 

This study is open to people who have previously been treated with a PARP inhibitor treatment and people who have not been previously treated with a PARP inhibitor. 

What the Study Involves

Participants will receive talazoparib orally once daily for 28 days. This cycle will be repeated every 28 days as long as there isn’t disease progression or unacceptable side effects. Participants will undergo biopsy at the start of the study and 4 hours after talazoparib dose on day 1 of cycle 2. Participants can elect to have another biopsy, either at the start of the next cycle or at the time of disease progression.

Study Locations




This Study is Open To:

Adults with the following may be eligible:

This Study is Not Open To:

People with the following may not be eligible: 


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.